Treatment of severe refractory pemphigus vulgaris with rituximab;Tratamiento de pénfigo vulgar grave resistente con rituximab

Actas Dermo-Sifiliograficas

Volumn 97, Issue 1, 2006, Pages 48-51

  Pitarch, Gerard ^a   Sánchez Carazo, José L ^a   Pardo, José ^a   Torrijos, Arantxa ^a   Roche, Elena ^a   Fortea, José M ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

Infliximab; Pemphigus foliaceus; Pemphigus vulgaris; Rituximab

Indexed keywords

AZATHIOPRINE; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEFLAZACORT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; THALIDOMIDE;

ADULT; AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PLASMAPHERESIS; REVIEW;

EID: 33645033349     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(06)73348-8     Document Type: Article

References (19)

1. Duchosal MA. B-cell development and differentiation. Semin Hematol. 1997;34:2-12.
2. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-52.
3. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother. 2004;58:299-309.
4. Borradori L, Lombardi T, Samson J. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137:269-72.
5. Rossum MM, Verhaegen NT, Jonkman MF. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leuk Lymph. 2004;45:2327-32.
6. Heizmann M, Itin P, Wernli M, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. Am J Hematol. 2001;66:142-4.
7. Goebeler M, Herzog S, Bröckner EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003;149:899-901.
8. Slifka MH, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol. 1998;10:252-8.
9. Pardo J, Mercader P, Mahiques L, Sánchez-Carazo JL, Oliver V, Fortea JM. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol. 2005;153:222-3.
10. Wagner CL, Schantz A, Barnathan E, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol. 2003;112:37-53.
11. Herrmann G, Engert A, Hunzelmann N. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003;148:602-3.
12. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51:817-9.
13. España A, Fernández-Galar M, Lloret P. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50:974-6.
14. Dupuy A, Viguier M, Bédane C. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140:91-6.
15. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica. 2003;88:ELT24.
16. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin Exp Dermatol. 2003;28:366-8.
17. Wenzel J, Bauer R, Bieber T, Tüting T. Successful treatment of severe pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol. 2004;85:185-6.
18. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. Arch Dermatol. 2002;47:785-8.
19. Rose AL, Smith BE, Maloney DG. Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptic effects. Blood. 2002;100:1765-73.